Showing results (101-110 of 272) with videos related to
Sort By:
Pageof 28
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|April 27, 2018
Blood-brain barrier transport kinetics of NOTA-modified proteins: the somatropin caseNathalie Bracke, Yorick Janssens, Evelien Wynendaele, et al.PET Clinics|May 10, 2016
PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and MetabolismVikas Prasad, Valentina Ambrosini, Abass Alavi, et al.PET Clinics|May 10, 2016
PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and MetabolismVikas Prasad, Valentina Ambrosini, Abass Alavi, et al.Clinical Imaging|September 13, 2005
Lung scintigraphy in the diagnosis and follow-up of pulmonary thromboembolism in children with nephrotic syndromeBhagwant Rai Mittal, Surjit Singh, Anish Bhattacharya, et al.Journal of Clinical Medicine|December 24, 2021
The Utility of Metabolic Parameters on Baseline F-18 FDG PET/CT in Predicting Treatment Response and Survival in Paediatric and Adolescent Hodgkin LymphomaJanet Denise Reed, Andries Masenge, Ane Buchner, et al.Pharmaceuticals (Basel, Switzerland)|May 20, 2017
Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone MetastasesNina Pfannkuchen, Marian Meckel, Ralf Bergmann, et al.Annals of Nuclear Medicine|August 16, 2025
Evaluating the diagnostic utility of [⁶⁸Ga]Ga-Pentixafor in solid tumors: a systematic reviewSaad Ruzzeh, Ahmed Saad Abdlkadir, Hasan Al-Alawi, et al.Neuroendocrinology|September 18, 2014
The status of neuroendocrine tumor imaging: from darkness to light?Lisa Bodei, Anders Sundin, Mark Kidd, et al.Journal of Neuroendocrinology|April 16, 2024
Use of approved Lu-177 radiopharmaceuticals in patients with end-stage renal disease: A review of the literature and proposed treatment algorithmNikolaos A Trikalinos, Hyun Kim, Anitha Vijayan, et al.Journal of Labelled Compounds & Radiopharmaceuticals|November 29, 2013
Production of high specific activity (195m) Pt-cisplatinum at South African Nuclear Energy Corporation for Phase 0 clinical trials in healthy individual subjectsJan Rijn Zeevaart, Judith Wagener, Biljana Marjanovic-Painter, et al.Pageof 28